CN114569515B - 一种医美术后皮肤屏障受损修复的水凝胶及其制备方法 - Google Patents
一种医美术后皮肤屏障受损修复的水凝胶及其制备方法 Download PDFInfo
- Publication number
- CN114569515B CN114569515B CN202210309848.7A CN202210309848A CN114569515B CN 114569515 B CN114569515 B CN 114569515B CN 202210309848 A CN202210309848 A CN 202210309848A CN 114569515 B CN114569515 B CN 114569515B
- Authority
- CN
- China
- Prior art keywords
- parts
- hydrogel
- essential oil
- extract
- medical arts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 230000008591 skin barrier function Effects 0.000 title claims abstract description 20
- 239000000341 volatile oil Substances 0.000 claims abstract description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 25
- 244000166675 Cymbopogon nardus Species 0.000 claims abstract description 19
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims abstract description 19
- 244000126014 Valeriana officinalis Species 0.000 claims abstract description 16
- 235000013832 Valeriana officinalis Nutrition 0.000 claims abstract description 16
- 235000016788 valerian Nutrition 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 108010039918 Polylysine Proteins 0.000 claims abstract description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 10
- 235000019218 bitter orange extract Nutrition 0.000 claims abstract description 10
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 10
- 239000000661 sodium alginate Substances 0.000 claims abstract description 10
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 9
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 9
- 235000011187 glycerol Nutrition 0.000 claims abstract description 9
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 9
- 235000020638 mussel Nutrition 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 244000183685 Citrus aurantium Species 0.000 claims description 11
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 230000008439 repair process Effects 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000010894 electron beam technology Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 240000004784 Cymbopogon citratus Species 0.000 claims description 3
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 229940074410 trehalose Drugs 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 8
- 235000014655 lactic acid Nutrition 0.000 abstract description 8
- 239000004310 lactic acid Substances 0.000 abstract description 8
- 230000006872 improvement Effects 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000037380 skin damage Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 241000207199 Citrus Species 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 235000010676 Ocimum basilicum Nutrition 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 235000020971 citrus fruits Nutrition 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- 241001529734 Ocimum Species 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102100023124 Mucin-13 Human genes 0.000 description 1
- 101710155074 Mucin-13 Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 240000006066 Rosa rugosa Species 0.000 description 1
- 235000000659 Rosa rugosa Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种医美术后皮肤屏障受损修复的水凝胶及其制备方法，所述水凝胶包括以下重量份的原料：透明质酸15‑20份、海藻酸钠10‑15份、甘油5‑10份、海藻糖8‑12份、ε‑聚赖氨酸3‑5份、香茅精油4‑6份、缬草精油5‑8份、玳玳花提取物9‑13份、青桔提取物10‑13份、类贻贝粘蛋白12‑15份。本发明所制备水凝胶具有良好的抗炎作用，而且保湿效果佳，促生长，促愈合，对医美术后受损皮肤屏障修复效率高，而且效果持久，其对医美术后皮肤屏障修复具有良好的效果，能够显著提高皮损改善率高，降低乳酸刺痛实验阳性率，同时提高角质层含水量。
Description
技术领域
本发明涉及水凝胶领域，特别涉及一种医美术后皮肤屏障受损修复的水凝胶及其制备方法。
背景技术
在医学美容领域，激光美容技术得到广泛的应用，如激光祛斑、激光祛痘等。激光美容技术具有安全性高、美容效果好等优点，受到广大爱美者的青睐，但是激光的光热效应也容易造成皮肤屏障受损，因此对医美术后受损皮肤屏障修复是必须的，也是非常关键。现有修复产品存在修复效果欠佳、修复效率慢、出现不良反应率高等问题。
发明内容
鉴于此，本发明提出一种医美术后皮肤屏障受损修复的水凝胶及其制备方法，制得水凝胶对医美术后皮肤屏障修复具有良好的效果，修复效果佳，而且修复效率高，无不良反应。
本发明的技术方案是这样实现的：一种医美术后皮肤屏障受损修复的水凝胶，包括以下重量份的原料：透明质酸15-20份、海藻酸钠10-15份、甘油5-10份、海藻糖8-12份、ε-聚赖氨酸3-5份、香茅精油4-6份、缬草精油5-8份、玳玳花提取物9-13份、青桔提取物10-13份、类贻贝粘蛋白12-15份。
进一步，包括以下重量份的原料：透明质酸18份、海藻酸钠12份、甘油8份、海藻糖10份、ε-聚赖氨酸4份、香茅精油5份、缬草精油7份、玳玳花提取物11份、青桔提取物12份、类贻贝粘蛋白13份。
进一步，所述香茅精油的制备方法：取香茅草粉末，采用超临界CO2萃取仪进行萃取，萃取压力为19MPa，萃取温度为60℃，萃取时间为30min，得到香茅精油。
进一步，所述缬草精油的制备方法：取缬草粉末，采用超临界CO2萃取仪进行萃取，萃取压力为23MPa，萃取温度为45℃，萃取时间为60min，得到缬草精油。
进一步，所述玳玳花提取物的制备方法：取玳玳花粉末，按照料液比1kg：5L加入蒸馏水，置于功率28kW条件微波处理30min，再置于水蒸气蒸馏提取，收集馏出液，用***萃取，收集萃取液，过滤，滤液旋蒸，45℃真空干燥30min，得到玳玳花提取物。
进一步，所述青桔提取物的制备方法：取青桔皮粉末，按照料液比1kg：8L加入70％wt的乙醇溶液，在300rpm、55℃条件下振荡1.5h，离心，取上清液，过滤，浓缩，干燥，得到青桔皮提取物。
进一步，所述的水凝胶的制备方法，包括以下步骤：按照料液质量比1：1备蒸馏水，将玳玳花提取物、青桔提取物加入三分之一量的蒸馏水中，搅拌混合，制得混合液；混合液在搅拌状态加入香茅精油和缬草精油，再加入类贻贝粘蛋白；最后加入余量蒸馏水以及透明质酸、海藻酸钠、甘油、海藻糖和ε-聚赖氨酸，在45-55℃搅拌22-28h，冷冻干燥，采用电子束辐照灭菌，其辐照剂量为20kGy，制得目标水凝胶。
与现有技术相比，本发明的有益效果是：
(1)本发明采用类贻贝粘蛋白结合青桔提取物、青桔提取物、香茅精油、缬草精油，添加ε-聚赖氨酸、海藻酸钠、海藻糖等，科学配比，制得水凝胶对医美术后皮肤屏障修复具有良好的效果，显著提高皮损改善率高，降低乳酸刺痛实验阳性率，同时提高角质层含水量。
(2)本发明所制备水凝胶具有良好的抗炎作用，而且保湿效果佳，促生长，促愈合，对医美术后受损皮肤屏障修复佳，而且修复效率高，且效果持久。
(3)采用本发明制备方法，利用电子束辐照灭菌，在保证功效成分生物活性的同时大大提高了使用的安全性。
具体实施方式
为了更好理解本发明技术内容，下面提供具体实施例，对本发明做进一步的说明。
本发明实施例所用的实验方法如无特殊说明，均为常规方法。
本发明实施例所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
实施例1-3
1配料比
| 序号 | 组分 | 实施例1(g) | 实施例2(g) | 实施例3(g) |
| 1 | 透明质酸 | 18 | 15 | 20 |
| 2 | 海藻酸钠 | 12 | 15 | 10 |
| 3 | 甘油 | 8 | 7 | 10 |
| 4 | 海藻糖 | 10 | 12 | 8 |
| 8 | ε-聚赖氨酸 | 4 | 5 | 3 |
| 5 | 香茅精油 | 5 | 4 | 6 |
| 6 | 缬草精油 | 7 | 8 | 5 |
| 7 | 玳玳花提取物 | 11 | 9 | 13 |
| 9 | 青桔提取物 | 12 | 10 | 13 |
| 10 | 类贻贝粘蛋白 | 13 | 15 | 12 |
2制备方法
2.1原料制备
(1)香茅精油的制备：取香茅草粉末，采用超临界CO2萃取仪进行萃取，萃取压力为19MPa，萃取温度为60℃，萃取时间为30min，得到香茅精油。
(2)缬草精油的制备方法：取缬草粉末，采用超临界CO2萃取仪进行萃取，萃取压力为23MPa，萃取温度为45℃，萃取时间为60min，得到缬草精油。
(3)玳玳花提取物的制备方法：取玳玳花粉末，按照料液比1kg：5L加入蒸馏水，置于功率28kW条件微波处理30min，再置于水蒸气蒸馏提取，收集馏出液，用***萃取，收集萃取液，过滤，滤液旋蒸浓缩，45℃真空干燥30min，得到玳玳花提取物。
(4)青桔提取物的制备方法：取青桔皮粉末，按照料液比1kg：8L加入70％wt的乙醇溶液，在300rpm、55℃条件下振荡1.5h，离心，取上清液，过滤，浓缩，干燥，得到青桔皮提取物。
2.2水凝胶制备
按照料液质量比1:1备蒸馏水，将玳玳花提取物、青桔提取物加入三分之一量的蒸馏水中，搅拌混合均匀，制得混合液；混合液在搅拌状态缓慢加入香茅精油和缬草精油，再在搅拌状态下加入类贻贝粘蛋白；最后加入余量蒸馏水以及透明质酸、海藻酸钠、甘油、海藻糖和ε-聚赖氨酸，在50℃搅拌24h，冷冻干燥，采用电子束辐照灭菌，辐照剂量为20kGy，制得目标水凝胶。
对比例1-本对比例与实施例1主要区别在于，类贻贝粘蛋白替换为等量的贻贝粘蛋白。其他组分与实施例1一致。
对比例2-本对比例与实施例1主要区别在于，香茅精油替换为等量的罗勒(OCIMUMBASILICUM)油。其他组分与实施例1一致。
对比例3-本对比例与实施例1主要区别在于，缬草精油替换为等量的薰衣草(LAVANDULAANGUSTIFOLIA)油。其他组分与实施例1一致。
对比例4-本对比例与实施例1主要区别在于，玳玳花提取物替换为等量的玫瑰(ROSARUGOSA)花提取物。其他组分与实施例1一致。
对比例5-本对比例与实施例1主要区别在于，青桔提取物替换为等量的柑橘(CITRUSRETICULATA)皮提取物。其他组分与实施例1一致。
对比例6-本对比例与实施例1主要区别在于原料配比不同：
一、小鼠试验
1试验方法
选择健康小鼠，随机分组，分别为对照组和给药组1-9，每组10只，在相同的环境下饲养7天。将小鼠背部两侧毛发用剃除干净，使小鼠背部两侧皮肤裸露，采用2940nm铒激光治疗仪照射小鼠左侧背部裸露皮肤，照射完成后给药组1-9分别立刻涂抹1mg/kg的水凝胶(给药组1-9分别对应实施例1-3、对比例1-6制得水凝胶)，对照组照射后不给药、涂抹等量纯水，然后将小鼠置于适宜条件下饲养，第2天观察小鼠激光照射部位皮肤变化并记录。每7天照射一次，持续照射4周。4周后，停止照射，将小鼠固定倒立，剪开颈部皮肤和动脉，用10mL离心管装取颈部动脉血，放置2h，转速3000rpm，离心10min。取上层血清，冷冻保存备用。按试剂盒检测说明书分别检测血清IL-6、INF-γ或TNF-α。
2结果
表1小鼠体内炎性因子
| IFN-γ(pg/ml) | TNF-α(ng/ml) | IL-6(pg/ml) | |
| 对照组 | 154.0±14.2 | 86.9±10.3 | 27.1±4.2 |
| 实施例1 | 14.1±3.3 | 25.2±2.5 | 8.3±1.2 |
| 实施例2 | 15.6±3.6 | 28.5±2.3 | 8.6±1.6 |
| 实施例3 | 15.2±3.7 | 27.9±2.1 | 8.5±1.5 |
| 对比例1 | 19.0±4.3 | 32.3±3.8 | 11.2±1.7 |
| 对比例2 | 17.9±4.8 | 30.7±3.3 | 10.1±1.8 |
| 对比例3 | 17.3±4.7 | 31.2±3.4 | 9.3±1.5 |
| 对比例4 | 17.1±4.5 | 30.3±3.9 | 9.8±1.8 |
| 对比例5 | 18.2±5.3 | 31.2±3.7 | 10.8±1.9 |
| 对比例6 | 16.7±4.2 | 29.9±3.6 | 9.1±1.4 |
结果表明，相比对照组，给药组1-9有效降低激光术后血清IL-6、INF-γ或TNF-α水平，具有显著差异。其中，给药组1-3(实施例1-3)效果明显优于给药组4-9(对比例1-6)。
其中，对比例1调整添加贻贝粘蛋白，对比例2调整添加罗勒(OCIMUM BASILICUM)油，对比例3调整添加薰衣草(LAVANDULAANGUSTIFOLIA)油，对比例4调整添加玫瑰(ROSARUGOSA)花提取物，对比例5调整添加柑橘(CITRUSRETICULATA)皮提取物，其效果均明显下降，表明本发明采用类贻贝粘蛋白结合本发明制备香茅精油、缬草精油、玳玳花提取物、青桔提取物，所制备水凝胶效果更佳。另外，对比例6减少类贻贝粘蛋白、青桔提取物、玳玳花提取物等用量，增加香茅精油、缬草精油等用量，其效果也有所下降，表明采用本发明配比的原料，有所提高产品的效果。
二、临床效果
1基本资料：收集激光祛斑术后的志愿者，随机分组，每组30人，研究组1-3分别使用实施例1-3水凝胶，所有志愿者均为女性，年龄范围为40-50岁。各组患者具有可比性，差异无统计学意义(P＞0.05)。
2纳入标准：
1)激光祛斑术后乳酸刺激试验总分≥2分；
2)无严重肝肾功能；损害和免疫异常等***性疾病患者；
3)3个月内面部未使用激素等药物治疗和其他美容治疗及可能影响结果的治疗；
4)无高敏体质者；
5)自愿参加试验，医丛遵医嘱配合治疗和随访者。
3排除标准：
(1)已知对本产品的成分过敏者；
(2)妊娠期或哺乳期妇女；
(3)治疗区域有明显感染者；
(4)3月内使用过激素或免疫抑制类药物者。
(5)患有精神类疾病或对其他因素不能配合治疗者。
4处理方法：使用前清洁脸部后，将水凝胶均匀涂抹脸部，静敷15-20分钟后清洗水凝胶。连续使用7天，观察修复情况。
5疗效判定
5.1皮损改善评价：
正常皮肤：皮肤无红斑瘙痒、干燥脱屑等症状；
轻度受损：皮肤轻度干燥瘙痒，无明显鳞屑、红斑及丘疹；
中度受损：皮肤中度干燥，有鳞屑发红及少数丘疹；
重度受损：皮肤干燥红斑、瘙痒明显，鳞屑较多，丘疹明显。
5.2乳酸刺激试验：乳酸刺激试验是判定敏感性皮肤的评价方法。
方法如下：洁面后，取50μl的10％乳酸溶液涂抹于鼻唇沟和任意一侧面颊，分别在2.5min和5min时评估，0分为无刺痛感，1分为轻度刺痛，2分为中度刺痛，3分为重度刺痛，两次分数相加总和≥3分者为乳酸刺痛反应阳性。注意记录治疗前后的分数。
5.3TEWL值检测：TEWL是指面部经皮水份丢失与角质层含水量，其数值越低，则角质层含水量数值越高，皮肤的屏障功能越好；反之则越差。TEWL值：健康状态(0-15)、亚健康状态(15-25)、疾病状态(＞25)。
6不良反应：定期随访，并记录是否发生瘙痒、红斑及丘疹脓疱等不良反应及情况。
7结果
表2水凝胶修复7天后情况
结果显示，采用实施例1-3水凝胶修复后皮损改善率高，乳酸刺痛实验阳性率明显下降，TEWL值在较低的水平，角质层含水量高。
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内，所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (8)
1.一种医美术后皮肤屏障受损修复的水凝胶，其特征在于，包括以下重量份的原料：透明质酸15-20份、海藻酸钠10-15份、甘油5-10份、海藻糖8-12份、ε-聚赖氨酸3-5份、香茅精油4-6份、缬草精油5-8份、玳玳花提取物9-13份、青桔皮提取物10-13份、类贻贝粘蛋白12-15份。
2.根据权利要求1所述的医美术后皮肤屏障受损修复的水凝胶，其特征在于，包括以下重量份的原料：透明质酸18份、海藻酸钠12份、甘油8份、海藻糖10份、ε-聚赖氨酸4份、香茅精油5份、缬草精油7份、玳玳花提取物11份、青桔皮提取物12份、类贻贝粘蛋白13份。
3.根据权利要求1所述的医美术后皮肤屏障受损修复的水凝胶，其特征在于，所述香茅精油的制备方法：取香茅草粉末，采用超临界CO2萃取仪进行萃取，萃取压力为19MPa，萃取温度为60℃，萃取时间为30min，得到香茅精油。
4.根据权利要求1所述的医美术后皮肤屏障受损修复的水凝胶，其特征在于，所述缬草精油的制备方法：取缬草粉末，采用超临界CO2萃取仪进行萃取，萃取压力为23MPa，萃取温度为45℃，萃取时间为60min，得到缬草精油。
5.根据权利要求1所述的医美术后皮肤屏障受损修复的水凝胶，其特征在于，所述玳玳花提取物的制备方法：取玳玳花粉末，按照料液比1kg：5L加入蒸馏水，置于功率28kW条件微波处理30min，再置于水蒸气蒸馏提取，收集馏出液，用***萃取，收集萃取液，过滤，滤液旋蒸，45℃真空干燥30min，得到玳玳花提取物。
6.根据权利要求1所述的医美术后皮肤屏障受损修复的水凝胶，其特征在于，所述青桔皮提取物的制备方法：取青桔皮粉末，按照料液比1kg：8L加入70％wt的乙醇溶液，在300rpm、55℃条件下振荡1.5h，离心，取上清液，过滤，浓缩，干燥，得到青桔皮提取物。
7.根据权利要求1-6任一项所述的水凝胶的制备方法，其特征在于，包括以下步骤：按照料液质量比1:1备蒸馏水，将玳玳花提取物、青桔皮提取物加入三分之一量的蒸馏水中，搅拌混合，制得混合液；混合液在搅拌状态加入香茅精油和缬草精油，再加入类贻贝粘蛋白；最后加入余量蒸馏水以及透明质酸、海藻酸钠、甘油、海藻糖和ε-聚赖氨酸，在45-55℃搅拌22-28h，冷冻干燥，采用电子束辐照灭菌，制得目标水凝胶。
8.根据权利要求7所述的水凝胶的制备方法，其特征在于，所述电子束辐照灭菌的辐照剂量为20kGy。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210309848.7A CN114569515B (zh) | 2022-03-28 | 2022-03-28 | 一种医美术后皮肤屏障受损修复的水凝胶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210309848.7A CN114569515B (zh) | 2022-03-28 | 2022-03-28 | 一种医美术后皮肤屏障受损修复的水凝胶及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114569515A CN114569515A (zh) | 2022-06-03 |
| CN114569515B true CN114569515B (zh) | 2023-07-07 |
Family
ID=81783086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210309848.7A Active CN114569515B (zh) | 2022-03-28 | 2022-03-28 | 一种医美术后皮肤屏障受损修复的水凝胶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114569515B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114948788B (zh) * | 2022-06-15 | 2023-11-24 | 绽妍生物科技有限公司 | 一种舒缓修护三重蛋白组合物及其应用 |
| CN115554456A (zh) * | 2022-10-11 | 2023-01-03 | 珠海市雅莎医疗器械有限公司 | 一种含海藻糖的皮肤屏障修复敷料及制备方法和应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151571A (zh) * | 2019-05-31 | 2019-08-23 | 旖帆(上海)实业有限公司 | 一种感温远红外亮白面膜 |
| CN110522713A (zh) * | 2019-08-14 | 2019-12-03 | 天津科技大学 | 一种抗皱去脂肪粒和黑眼圈的奶基质脂质体眼霜及其制备方法 |
| CN111437436A (zh) * | 2020-05-25 | 2020-07-24 | 绽妍生物科技有限公司 | 一种用于皮肤浅表损伤高效修复的膏体伤口敷料及其制备方法 |
| CN111467562A (zh) * | 2020-05-25 | 2020-07-31 | 绽妍生物科技有限公司 | 一种用于皮肤浅表损伤快速修复的液体伤口敷料及其制备方法 |
| CN111956860A (zh) * | 2020-09-07 | 2020-11-20 | 海南鸿翼医疗器械有限公司 | 一种皮肤屏障创面修复的液体海藻糖敷料及其制备方法 |
| CN113368300A (zh) * | 2021-05-31 | 2021-09-10 | 绽妍生物科技有限公司 | 一种eps与贻贝提取物复配修复皮肤屏障敷料及其制备方法 |
| CN113769066A (zh) * | 2021-09-17 | 2021-12-10 | 成都英普博集生物科技有限公司 | 一种促进创面愈合的组合物及其制备方法与用途 |
-
2022
- 2022-03-28 CN CN202210309848.7A patent/CN114569515B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151571A (zh) * | 2019-05-31 | 2019-08-23 | 旖帆(上海)实业有限公司 | 一种感温远红外亮白面膜 |
| CN110522713A (zh) * | 2019-08-14 | 2019-12-03 | 天津科技大学 | 一种抗皱去脂肪粒和黑眼圈的奶基质脂质体眼霜及其制备方法 |
| CN111437436A (zh) * | 2020-05-25 | 2020-07-24 | 绽妍生物科技有限公司 | 一种用于皮肤浅表损伤高效修复的膏体伤口敷料及其制备方法 |
| CN111467562A (zh) * | 2020-05-25 | 2020-07-31 | 绽妍生物科技有限公司 | 一种用于皮肤浅表损伤快速修复的液体伤口敷料及其制备方法 |
| CN111956860A (zh) * | 2020-09-07 | 2020-11-20 | 海南鸿翼医疗器械有限公司 | 一种皮肤屏障创面修复的液体海藻糖敷料及其制备方法 |
| CN113368300A (zh) * | 2021-05-31 | 2021-09-10 | 绽妍生物科技有限公司 | 一种eps与贻贝提取物复配修复皮肤屏障敷料及其制备方法 |
| CN113769066A (zh) * | 2021-09-17 | 2021-12-10 | 成都英普博集生物科技有限公司 | 一种促进创面愈合的组合物及其制备方法与用途 |
Non-Patent Citations (2)
| Title |
|---|
| 苏珊·柯蒂斯等著.《芳香精油宝典》.中国轻工业出版社,2018,第78、139页. * |
| 陈仁寿等主编.《江苏中药志》.江苏凤凰科学技术出版社,2020,第226页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114569515A (zh) | 2022-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114569515B (zh) | 一种医美术后皮肤屏障受损修复的水凝胶及其制备方法 | |
| EP1663104B1 (en) | Spongilla-based therapeutic compositions for treating and preventing acne | |
| CN109125107B (zh) | 一种有效改善和修复面部激素依赖性皮炎的多肽组合物 | |
| US20190358270A1 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
| KR102526210B1 (ko) | 매스틱검 추출 발효물을 유효성분으로 포함하는 피부재생 또는 피부 상처 개선용 화장료 조성물 및 이의 제조방법 | |
| KR102071627B1 (ko) | 피부 각질제거용 필링 겔 조성물 및 그 제조방법 | |
| CN112322681B (zh) | 一种中药五谷虫活性肽及其制备方法和用途 | |
| CN115414299B (zh) | 一种舒缓修护冻干喷雾 | |
| CN113144115A (zh) | 一种治疗寻常疣的中药组合物及其应用 | |
| CN108078868A (zh) | 一种用于护肤品的抗过敏组合物 | |
| CN114948859A (zh) | 一种治疗泛发性皮炎的中药组合物皮肤用凝胶剂及其制备方法和应用 | |
| CN113599498A (zh) | 复合抑菌肽及制备方法、快速止痛蜂毒调理膏及制备方法 | |
| CN105250838B (zh) | 一种治疗胼胝的化妆品 | |
| TWI333420B (en) | Vapor fraction from seeds of glycine max (l.) merr. and composition thereof | |
| CN115192639B (zh) | 一种治疗湿疹的药物及其制备方法 | |
| CN110302132A (zh) | 一种含蜗牛分泌物滤液的修复喷剂及其制备方法 | |
| CN113069389A (zh) | 一种甘草抗敏修复精华液及制备方法 | |
| CN114748631B (zh) | 一种皮肤损伤修复组合物及其制备方法和药物 | |
| CN105232650B (zh) | 一种治疗烫伤的药膏及其制备和使用方法 | |
| CN113440590B (zh) | 一种治疗癌性疼痛的外用蟾雄膏 | |
| CN108703901A (zh) | 一种祛痘霜的制备方法 | |
| CN116832086B (zh) | 一种治疗皮肤皲裂的外用中药组合物及其用途 | |
| CN113995701B (zh) | 一种祛痘和消除痘印的组合物及其制备方法和应用 | |
| CN114886794B (zh) | 一种具有抗炎和抗氧化作用的组合物及其应用 | |
| CN109674890B (zh) | 预防和/或治疗皮肤红血丝的组合物和护肤品及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: No. 3701, 37th Floor, Building 2, No. 666, Middle Tianfu Avenue, Chengdu High-tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu, Sichuan 610000 Patentee after: Chunyan Biotechnology Co.,Ltd. Address before: 37th floor, building 2, No. 666, middle section of Tianfu Avenue, Chengdu hi tech Zone, China (Sichuan) pilot Free Trade Zone, Chengdu, Sichuan 610000 Patentee before: Chayan Biotechnology Co.,Ltd. |
|
| CP03 | Change of name, title or address |